Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 25;15(9):e0239769.
doi: 10.1371/journal.pone.0239769. eCollection 2020.

Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome

Priya M Mathews  1 , Susan A Robinson  2 , Anisa Gire  1 , Alan N Baer  2 , Esen K Akpek  1   2
Affiliations

Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome

Priya M Mathews et al. PLoS One. .

Abstract

Purpose: To report the significance of extraglandular ocular involvement and long-term systemic morbidity and mortality in primary Sjögren's Syndrome (SS).

Methods: This retrospective, longitudinal cohort study included consecutive patients with primary SS evaluated at a tertiary referral center. An electronic chart review was performed and all available data were extracted from clinic visits between October 1999 and March 2019. The primary outcome measures included occurrence of extraglandular ocular manifestations of SS, serological markers, prevalence of malignancy, and incidence of death.

Results: One hundred and twenty-six SS patients with minimum 3 years of follow-up (median 9.6, range 3.0-15.9 years, total of 1,235 patient-years) were included. Of those, 10 patients with inflammatory keratolysis or scleritis had 2.3 times greater likelihood of death compared to the rest of the cohort (OR = 2.3, 95% confidence interval [CI] 0.5 to 4.0, p = 0.01) due to SS related complications. The lifetime prevalence of any malignancy in the entire cohort was 15.5%. The most common hematologic malignancy was non-Hodgkin's lymphoma (4.8%) and the most common solid malignancy was breast cancer (6.0%). Men SS patients were more likely to have a history of or concurrent malignancy compared to women (30.0% versus 13.7%, p = 0.16) and double the mortality (OR = 2.1, 95% CI 0.09 to 1.4, p = 0.04), independent of malignancy.

Conclusions: SS patients with serious ocular manifestations, particularly men, may be at greater risk for mortality due to SS complications. The eye seems to be the barometer of systemic disease activity.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist. Dr. Akpek is an unpaid member of the Sjögren’s Foundation.

References

    1. Fox RI. Sjogren's syndrome. Lancet. 2005;366(9482):321–31. 10.1016/S0140-6736(05)66990-5 - DOI - PubMed
    1. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983–9. 10.1136/annrheumdis-2014-205375 - DOI - PubMed
    1. Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270–80. - PubMed
    1. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis. 2005;64(3):347–54. 10.1136/ard.2004.025676 - DOI - PMC - PubMed
    1. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum. 2000;29(5):296–304. 10.1016/s0049-0172(00)80016-5 - DOI - PubMed

Publication types